How Diagnostics Companies Can Use Real-World Clinical Data to Drive Adoption in 2026: A Complete Guide to Mapping Demand With CPT, Claims, and Clinical Activity Insights

In 2026, diagnostic companies face a dramatically evolving commercial landscape. Clinical adoption cycles are shortening, reimbursement requirements are tightening, and precision medicine competition is accelerating.

At the same time, diagnostics teams have access to unprecedented amounts of real-world clinical data — including claims utilization patterns, CPT/HCPCS volumes, facility affiliations, and provider connections — that can transform product strategy, targeting, and launch execution.

This article explains how diagnostics companies can use real-world data to drive adoption and how to map demand using CPT and claims insights.

Where helpful, it links to authoritative external sources and Alpha Sophia resources (raw URLs provided).

Why Diagnostics Companies Must Use Real-World Clinical Data (RWD) to Drive Adoption

High complexity requires precise targeting

Diagnostic adoption depends on:

• which specialties see the right patients,

• which clinicians perform relevant procedures,

• which facilities concentrate specific diagnostic pathways,

• where clinical activity is trending upward.

LEK Consulting outlines how diagnostics growth now comes from real-world utility and clinical workflow integration, not just technology:

https://www.lek.com/insights/hea/us/ei/research-tools-and-diagnostics-outlook-and-industry-trends-2024

Traditional market sizing is no longer sufficient

Literature reviews or expert interviews cannot reveal:

• who is actually delivering relevant care today,

• which specialties generate the most testable patients,

• which outpatient settings dominate clinical activity,

• which physicians have growing procedural volumes,

• where market saturation vs. opportunity exists.

Only real-world data — especially claims, CPT activity, affiliations, and provider-level patterns — can provide accurate, timely targeting.

How Real-World Data Helps Diagnostic Companies Drive Adoption

1. Identify high-volume specialties and sub-specialties

Claims and CPT activity show which specialties treat the most patients aligned with the diagnostic pathway. This reveals:

• primary buyers,

• secondary contributors,

• niche subspecialists,

• unexpected high-volume segments.

2. Calculate geographic hotspots of diagnostic demand

Procedure utilization varies significantly by region. Claims data exposes:

• fastest-growing metropolitan areas,

• high-volume states,

• pockets of relevant specialty density,

• rural vs. urban usage differences.

By aligning GTM planning with geographic concentration, diagnostic companies maximize launch efficiency.

3. Understand facility-level clinical activity patterns

Not all facilities contribute equally. Real-world data helps teams distinguish between:

• academic centers,

• community hospitals,

• specialty clinics,

• outpatient centers,

• ASCs (Ambulatory Surgery Centers).

These differences can fundamentally shape diagnostic adoption.

Claims and affiliation data highlight where relevant patient activity actually occurs.

4. Identify multi-site clinicians and connected provider networks

Physicians practicing at multiple facilities often influence:

• where diagnostic workflows are implemented,

• how ordering pathways are standardized,

• cross-site adoption of new tests.

Connections based on shared affiliations, cross-facility practice patterns, or specialty cluster relationships are invaluable for identifying clinicians who can drive broader adoption.

5. Forecast adoption using CPT and procedure data

Real-world CPT codes reveal exactly how many potential diagnostic patients exist in each:

• specialty,

• region,

• facility type.

This enables:

• accurate TAM/SAM/SOM modeling,

• launch forecasting,

• proactive resource allocation,

• realistic revenue modeling.

This is dramatically more reliable than disease prevalence-based models.

How to Build a Real-World Data Demand Map (Step-by-Step)

Step 1: Identify relevant CPT/HCPCS codes

Map all codes tied to the clinical workflow your diagnostic supports.

Examples:

• Oncology → biopsy, imaging, pathology codes

• Cardiology → stress tests, echocardiograms

• GI → endoscopies, colonoscopies

• Infectious disease → molecular lab testing codes

• Women’s health → OB/GYN diagnostic panels

Capturing the full code range avoids underestimating opportunity.

Step 2: Analyze claims volumes across specialties

Claims reveal:

• which specialties most frequently perform relevant procedures,

• intensity and frequency of activity,

• which clinician types engage deeply in diagnostic workflows.

This identifies your real clinical buyer personas.

Step 3: Segment by facility type

Different facilities adopt diagnostics at different speeds.

Data reveals which environments offer:

• fastest adoption,

• highest throughput,

• strongest reimbursement alignment,

• most relevant patient flows.

Claims + affiliations = accurate facility targeting.

Step 4: Identify clinicians with multi-site influence or growing patient volume

Instead of referral flows, diagnostics companies can identify influence through:

• multi-facility practice footprints,

• shared clinical networks,

• overlapping team memberships,

• increasing CPT volumes,

• clinical growth trajectories.

These clinicians often accelerate adoption across multiple endpoints.

Alpha Sophia describes connected-provider logic 👉 here.

Step 5: Identify early-adopter segments

Diagnostics adoption tends to be highest among:

• high-volume proceduralists,

• clinicians with multi-site coverage,

• specialists with high patient turnover,

• providers engaged in innovation or niche subspecialties,

• physicians with administrative or quality-improvement roles.

More guidance on identifying high-value experts.

Use Case: Launching a New Diagnostic Test Using Real-World Data

A diagnostics company launching a new test can use real-world CPT and claims analytics to:

1. Identify high-volume clinical specialties.

2. Map geographic concentrations of relevant patient pathways.

3. Target the facility types most likely to adopt early.

4. Identify clinicians practicing at multiple facilities.

5. Build precise activation lists for early outreach.

Further interesting reads:

• FDA Real-World Evidence Program:

  https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

• BCG Diagnostics Commercialization Strategy:

  https://www.bcg.com/publications/2023/bringing-advanced-diagnostic-testing-to-market

• McKinsey: Digital Diagnostics a path forward for IVD

• https://www.mckinsey.com/industries/life-sciences/our-insights/digital-diagnostics-a-path-forward-for-ivd

Conclusion

Real-world clinical data — especially claims, CPT utilization, affiliations, and provider-level clinical patterns — is now the foundation of successful diagnostic commercialization. This approach enables companies to:

• predict demand accurately,

• target specialties with precision,

• prioritize geographies intelligently,

• design better launch strategies,

• identify influential clinicians early.

Alpha Sophia provides the analytics infrastructure to power this data-driven approach across every diagnostic product lifecycle stage.